Gilead Sciences (GILD) Submits NDA for Filgotinib for Treatment of Adults With Rheumatoid Arthritis in Japan

October 8, 2019 6:21 AM
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles